Beyond Biotech - the podcast from Labiotech

1:37 Labiotech.eu news3:34 Cradle19:47 Rani TherapeuticsThis week, we have two guests. We have conversations with Talat Imran, CEO of Rani Therapeutics; and Stef van Grieken, CEO and co-founder of Cradle.Rani Therapeutics - aiming to remove the pain of needlesRani Therapeutics Holdings, Inc., a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, has announced topline results from part 2 (the repeat-dose portion) of the phase 1 study of RT-102, the RaniPill GO capsule containing a proprietary formulation of human parathyroid hormone (1-34) analog (PTH) being developed for the treatment of osteoporosis. The study achieved all of its endpoints, with repeat doses of RT-102 being generally well tolerated and delivering the drug with high reliability to participants via the RaniPill GO.With these data, in total, 185 RaniPill GO capsules have now been administered to more than 90 participants in clinical studies, in addition to over 1,700 RaniPill capsules administered to animals in preclinical studies. In the clinical studies, the RaniPill capsule has been well tolerated and delivered its drug payload with high reliability and with bioavailability comparable to or better than subcutaneous injection.“The repeat-dose data contribute to our growing body of preclinical and clinical data that we believe support the viability of the RaniPill platform to orally deliver biologics and drugs to treat chronic diseases,” said Talat Imran, CEO of Rani. “These data give us confidence to move forward with multiple programs in parallel, including our ustekinumab biosimilar and adalimumab biosimilar programs, and to expand manufacturing scale-up. We can see a future where millions of patients no longer carry the burden of regular injections.”Startup Cradle raises $5.4M to design protein machines and cell factories with AICradle, a Dutch startup, has received €5.5 million ($5.4 million) in seed funding to further help scientists design and program proteins to produce a wide variety of everyday products including milk and meat.Cradle uses synthetic biology, adapting the genes of microorganisms such as bacteria and fungi, to create ‘cell factories’ that use programmable proteins to make a number of products without farming animals, to plastics created without petrochemicals, materials for clothing or electronic components, or even personalized medicines.

2:19 Labiotech.eu news4:37 CellCentric12:21 MicrofluidX29:12 Potter ClarksonThis week, we have three guests. We have conversations with Antoine Espinet, CEO of MicrofluidX; Will West, CEO of CellCentric; and Sara Holland, patent attorney at Potter Clarkson.MicrofluidX raises £3.3M to develop advanced therapy manufacturing platformMicrofluidX (MFX), a U.K. based provider of next-generation bioreactors for cell research and manufacturing, today announces £3.3 million ($4 million) of secured investments, bringing the company’s total funding to date to £7 million ($8.5 million). MFX’s next generation platform, the Cyto Engine, addresses the need for an affordable, scalable cell culture platform to revolutionize research, facilitate large-scale manufacture, and enable widespread access to advanced therapies.  “Advanced therapy manufacturing is hindered by out of date, inadequate manufacturing technologies,” said Antoine Espinet, CEO of MFX. “Our aim to commoditize manufacturing for cell and gene therapies through automation, digitalization, and the adoption of machine learning is supported by our investors, who appreciate the incredible impact this could have on the cell and gene therapy sector, and ultimately patients around the world.”MFX said it is addressing the two large pain points faced by the advanced therapies industry, commercialization and clinical translation. By providing a scalable bioprocessing platform with complete integration of online process analytical tools and data analytics powered by machine learning, the company hopes the Cyto Engine will reduce the cost and time of advanced therapy development and help bring these life-saving treatments to patients. Potter Clarkson patent attorney, Sara HollandSara Holland is a former research scientist turned patent attorney in the U.K. After finishing her PhD in engineering artificial yeast chromosomes, Holland carried out seven years of postdoctoral research at the University of Nottingham. This gave her a good understanding of the challenges that scientists face when she moved over to Potter Clarkson, an IP law firm.In her work as a patent attorney she helps universities, technology transfer departments and SMEs protect their inventions, with a focus on synthetic biology.Holland also co-founded the Women in Synthetic Biology Network, a group that aims to support gender diversity and support women working in the field of synthetic biology.CellCentric presents early clinical data at ASH CellCentric, a clinical stage biotechnology company pioneering small molecule inhibition of p300/CBP to treat cancer, announced clinical data for the first time at the 64th American Society of Haematology (ASH) annual meeting in New Orleans. To date, 26 patients with relapsed/refractory multiple myeloma (RRMM) have been treated with inobrodib as monotherapy, including seven most recently at the recommended phase 2 dose and dose schedule (RP2D). Treatment has been generally well-tolerated with the majority of on-target toxicities being mild or moderate in severity. Among the patients treated at the RP2D, six out of seven patients had reduction or stabilization of serum free light chains. One patient saw an unconfirmed complete response (CR), which went on to become a durable confirmed very good partial response (VGPR); a second patient demonstrated a confirmed partial response (PR); and a third currently has an unconfirmed PR (by IMWG response criteria).  These three patients remain on treatment after more than eight months.

2:33 Labiotech.eu news5:03 Humacyte23:01 Transgene37:21 Center for Global Development54:32 JLLThis week, we have three interviews. One is from Bio-Europe, a chat with Transgene chief business officer, Steven Bloom, and we also have conversations with Humacyte CEO Laura Niklason, and with Anthony McDonnell, Senior Policy Analyst at the Center for Global Development, on the subject of antimicrobial resistance.We also have our weekly commentary from Travis McCready at JLL.HumacyteThe ongoing war in Ukraine continues to present significant challenges for frontline hospitals in treating the injured. As part of the humanitarian aid effort, U.S. biotech, Humacyte, has worked with the FDA and the Ukrainian Ministry of Health to send 30 investigational bioengineered blood vessels to help repair tissue injuries from bomb and gunshot wounds. Humacyte’s human acellular vessels, or HAVs, are off-the-shelf replacement vessels that help the body heal itself. They are currently being evaluated in multiple advanced-stage clinical trials in vascular trauma  repair, arteriovenous access for hemodialysis and peripheral arterial disease and so far, have been implanted in more than 500 patients to date.   The HAV is made by seeding vascular cells from a qualified cell bank onto a biocompatible, biodegradable polymer mesh in a bioreactor bag. Over weeks, the cells grow and create new tissue, forming a tube-shaped vessel structure while the polymer mesh degrades. The resulting bioengineered vessel is then decellularized to create the HAV: an extracellular matrix that retains the biomechanical properties of the vessel but is cleansed of cellular components that could induce an immune response. The HAV in the bioreactor bag can then be shipped, stored, and is immediately available when needed.  Reaction to European Union action on antimicrobial resistanceFourteen Member States wrote to the European Commission recently outlining why they think the EU’s proposed policies around antimicrobial resistance (AMR) are costly, inefficient, and will disrupt the market for generic drugs.Anthony McDonnell, senior policy analyst at the Center for Global Development, looked in detail at the EU’s proposals, why member states are revolting against it, and which policies the EU should actually implement to successfully combat AMR.He said that, for months it has been speculated that the EU may move toward transferable exclusivity vouchers (TEVs). The14 countries have made three counter proposals for how new antimicrobials can be encouraged. TransgeneTransgene is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. Its programs utilize viral vector technology with the goal of indirectly or directly killing cancer cells.The company’s clinical-stage programs consist of two therapeutic vaccines (TG4001 for the treatment of HPV-positive cancers, and TG4050, the first individualized therapeutic vaccine based on the myvac platform) as well as two oncolytic viruses (TG6002 for the treatment of solid tumors, and BT-001, the first oncolytic virus based on the Invir.IO platform).With Transgene’s myvac platform, therapeutic vaccination enters the field of precision medicine with a novel immunotherapy that is fully tailored to each individual. myvac  allows the generation of a virus-based immunotherapy that encodes patient-specific mutations identified and selected by AI capabilities provided by its partner NEC.With its proprietary platform Invir.IO, Transgene is designing a new generation of multifunctional oncolytic viruses. It has an ongoing collaboration with AstraZeneca.Subscribe to our newsletter

2:40 Labiotech.eu news4:58 SOTIO Biotech13:43 Eversana19:37 Carl Borrebaeck36:42 Concarlo TherapeuticsThis week, we have four interviews: Franjo Hanzl, vice president commercial development Europe at Eversana; Stacy Blain, founder and CEO of Concarlo Therapeutics; Jens Hennecke, chief business officer at SOTIO Biotech; and Carl Borrebaeck, chairman of the board of directors of Immunovia and professor at the Department of Immunotechnology at the University of Lund in Sweden.Concarlo TherapeuticsConcarlo Therapeutics is a U.S.-based preclinical-stage precision-medicine oncology company. It is developing a novel therapy for drug-resistant metastatic breast cancer as a first indication.Concarlo’s patented IpY, a novel therapeutic peptide, will be the first to hit two targets, both CDK4/6- driven cell proliferation and CDK2-driven drug resistance at the same time, and the first to target p27. It is a specific cellular pathway to kill cancer cells rather than just slowing their proliferation.The novel approach relies on the role of p27Kpi, a natural inhibitor, an  "on-off" switch that regulates the activities of the major cancer-related proteins, CDK6, CDK4, and CDK2. EversanaEversana is a provider of global services to the life sciences industry. Its integrated solutions are rooted in the patient experience and span all stages of the product life cycle to deliver long-term, sustainable value for patients, prescribers, channel partners and payers. The company serves more than 500 organizations, including start-ups and established pharmaceutical companies, to advance life sciences solutions.Labiotech spoke with Franjo Hanzl, vice president commercial development Europe, at the Medicon Valley Alliance annual summit in Copenhagen, Denmark.Medicon VillageDuring NLS Days, Labiotech visited Medicon Village, in Lund, Sweden. While there, we had the opportunity to chat with Carl Borrebaeck. To say he’s involved in biotech would be an understatement. He is chairman of the board of directors of Immunovia and professor at the Department of Immunotechnology at the University of Lund in Sweden, as well as being director of Create Health. Borrebaeck, former vice president of the University of Lund, has been involved in many companies throughout his career, including Alligator Bio, SenzaGen and PainDrainer. He received the AKZONobel Science Award 2009, for contributions to cancer proteomics and antibody-based therapy, a Research! Sweden Award 2012 for his medical research of value for patients and health organizations, and the Royal Academy of Engineering Sciences Gold Medal 2012 for outstanding contributions to biomedical science. He was honored as the Biotech Builder of the Year in 2017.SOTIO BiotechSOTIO Biotech is a clinical stage immuno-oncology company owned by PPF Group based in Prague, Czechia. The company is building a pipeline of oncology programs by pursuing promising early-stage candidates through strategic licensing, M&A and in-house discovery efforts. SOTIO has been active in the clinic in 2022. The company initiated two clinical trials, the first was a phase 2 study for its lead IL-15 superagonist, SOT101. The initiation of the AURELIO-04 trial comes on the heels of positive phase 1/1b data, which showed 15 of 19 patients with advanced/metastatic solid tumors demonstrated clinical benefit with SOT101 in combination with pembrolizumab. The company also plans to enter the CAR-T space with the initiation of its BOXR trial in Q4 2022.  SOTIO is well funded into 2023 and plans to use those funds for posting more data across its already promising programs.We spoke with SOTIO Biotech at BIO-Europe.  

1:45 Labiotech.eu news4:02 PsychoGenics20:56 Destiny Pharma36:30 QureTech Bio54:41 AiCuris70:45 JLLThis week, we have three interviews on the theme of antimicrobial resistance (AMR), to mark World Antimicrobial Awareness Week. We spoke with Holger Zimmermann, CEO of anti-infectives company AiCuris; Neil Clark, CEO of Destiny Pharma, and Fredrik Almqvist, co-founder of QureTech Bio.We also have an interview with the chief scientific officer at PsychoGenics, Mark Varney. We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. Next week, we will be moderating a webinar on the microbiome, hosted by our sister company IN-PART. You can register here.World Antimicrobial Awareness WeekAs a result of drug resistance, antibiotics and other antimicrobial medicines may become ineffective and infections become increasingly difficult or impossible to treat. A global action plan to tackle the growing problem of resistance to antibiotics and other antimicrobial medicines was endorsed at the 68th World Health Assembly in 2015. A key objective of the plan is to improve awareness and understanding of AMR through effective communication, education and training.World Antimicrobial Awareness Week is a global campaign to improve awareness and understanding of AMR. Emyria commences US preclinical program with PsychoGenicsEmyria Limited, a clinical stage biotech, is working with PsychoGenics, a specialist neuroscience preclinical drug discovery and contract research organization (CRO). Emyria and partner, the University of Western Australia, will start by screening five novel MDMA analogs from their proprietary library using PsychoGenics’ advanced drug discovery platform, SmartCube. SmartCube employs computer vision and artificial intelligence (AI) to extract and analyze behavioral and physiological data from mice. These data can help predict the clinical effects of new drug compounds by comparing the novel drug’s effects to reference drug libraries. The automated testing platform offers an effective approach to the discovery and development of the next generation of breakthrough treatments for neurological disorders and can significantly reduce the time and cost to reaching approved Investigational New Drug status. PsychoGenics and Emyria have agreed to work collaboratively (at their own costs) in the initial phase, before exploring drug discovery and commercialization partnership models. PsychoGenics’s specialist drug screening platforms have been used in shared-risk partnerships with major pharmaceutical companies, including Sunovion and Roche, resulting in the discovery of several novel compounds now in clinical trials or advanced preclinical development. A successful partnership with Emyria could accelerate the development of Emyria’s novel MDMA-inspired drug candidate library, built with the University of Western Australia, into new treatments for severe neuropsychiatric disorders. PsychoGenics has successfully identified novel treatment candidates for serious and complex neuropsychiatric disorders via its proprietary SmartCube platform as well as formed innovative partnerships with major Pharmaceutical companies.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Connect with uslabiotech.euSubscribe to our newsletter

1:32 Labiotech.eu news4:02 PacBio34:02 Sierra Space57:12 JLLThis week, we have two longer interviews. We have conversations with Neil Ward, VP of PacBio EMEA, and Marc Giulianotti, senior manager in space biomanufacturing at Sierra Space.We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. Sierra Space and UC San Diego to develop first stem cell research institute in spaceSierra Space and University of California San Diego, one of the world’s top 15 research universities and a leader in microgravity research, have formed a new agreement with the goal of defining the future of human health care research in space.In a new memorandum of understanding between the two organizations, Sierra Space and UC San Diego will collaborate on Orbital Reef, the first commercial space station in low Earth orbit (LEO), to expand the university’s Integrated Space Stem Cell Orbital Research (ISSCOR) program, which is currently operational on the International Space Station (ISS). Together they will help define and shape the future of biotech and biopharma research and development in microgravity.PacBio launches Onso and Revio sequencing systemsPacBio recently announced beta testing of its Onso Sequencing System. The benchtop short-read DNA sequencing platform is expected to provide a new level of accuracy by utilizing PacBio’s sequencing by binding (SBB) technology.The Onso Sequencing System has been designed for compatibility with the rich ecosystem of products currently available for short-read sequencers and supports a diverse set of library preparation types, single cell analysis solutions, whole-genome sequencing and other targeted methods, such as amplicon and hybridization capture panels. It is anticipated to deliver 500 million reads per run and offer 200 and 300 cycle kits enabling paired and single end reads, at a list price of US $259,000 per system.The Revio long-read sequencing system will enable customers to scale their use of PacBio’s HiFi sequencing technology. Revio is designed to provide customers with the ability to sequence up to 1,300 human whole genomes per year at 30-fold coverage for less than $1,000 per genome. PacBio believes Revio will enable the use of HiFi sequencing for large studies in human genetics, cancer research, agricultural genomics, and more.Scientists have achieved many ‘firsts’ with HiFi sequencing on PacBio’s Sequel IIe sequencing system – the first complete telomere-to-telomere assembly of a human genome (Nurk 2022), the first haplotype-resolved methylomes in a rare disease cohort (Cheung 2022), the first population surveys of structural variation with long reads (All of Us Research Program), the first single-cell full isoform catalogs (Al'Khafaji 2021), and the first complete assembly of the highly complex oat genome (European Seed 2020). Revio uses the same HiFi chemistry – producing accurate native long reads with uniform coverage, extraordinary application performance for variant calling and assembly, and accurate DNA methylation detection – but at a much larger scale.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter

1:41 Labiotech.eu news4:17 Longevity Science Foundation23:07 HTID35:56 CanSinoBio54:47 JLLThis week, we have three interviews, and four guests. We chat with Pierre Corneille VP of the HTFC, which is responsible for HealthTech Innovation Days; Sergey Jakimov, co-founder and managing partner of LongeVC and the Longevity Science Foundation's CEO Lisa Ireland; and Pierre Morgon, executive vice president of CanSinoBIO. We also have our weekly contribution from global commercial real estate services company JLL, with Travis McCready. HealthTech Innovation Days brings European healthtech ecosystem togetherThe 4th edition of HealthTech Innovation Days (HTID), organized by HealthTech For Care, took place recently in Paris, France.The two-day event had the objective of finding financing and encouraging new industrial partnerships to accelerate the development and market access of new products and treatments for all patients. Around 1,600 formal and informal face-to-face and virtual meetings were organized this year, alongside 19 round table discussions. The event brought together more than 165 European health technology companies, 15 pharmaceutical and industrial companies and more than 300 international investors. 86 international experts gathered and animated 19 round tables. CanSinoBIO presents data on inhaled COVID vaccineCanSino Biologics Inc. presented clinical trial data for the recombinant COVID-19 vaccine (adenovirus type 5 vector) for inhalation (with the trade name Convidecia Air) at World Vaccine Congress (WVC) Europe recently in Barcelona, Spain. Jean-Denis Shu, vice president for medical affairs of CanSino Biologics showed Convidecia Air induces a strong and lasting immune response, with greater immunogenicity against the Omicron variant than recombinant protein or inactivated vaccines. International nonprofit Longevity Science Foundation expands to U.S. with new CEOThe Longevity Science Foundation (LSF), a global nonprofit organization providing research funding to establish a longer and healthier human lifespan, has recently expanded by launching operations in the U.S. and appointing a new president & CEO, Lisa E. Ireland. A group of physicians, investors, and other stakeholders founded the Longevity Science Foundation in 2021 to convene biotech founders, physicians, and research institutions in pursuit of lengthening the healthy human lifespan. The Foundation uses a blockchain-based voting platform to distribute grant funding to projects advancing longevity science, focusing on therapeutics, artificial intelligence, personalized medicine and predictive diagnostics. SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter

5:33 e-therapeutics21:25 BioWin 32:46 CMT Research Foundation57:47 JLLThis week, we have three interviews, and four guests. We chatted with Keith Fargo, chief scientific officer at the CMT Research Foundation; François Colery, head of the Talent Now initiative and Sylvie Ponchaut, managing director, from BioWin; and e-therapeutics’ CEO, Ali Mortazavi. We also have our weekly contribution from global commercial real estate services company JLL, with Robert Coughlin, managing director and New England Life Science Practice Group lead. CMT Research Foundation supports SamsaraThe CMT Research Foundation (CMTRF), a non-profit focused solely on delivering treatments and cures for Charcot-Marie-Tooth disease, has invested in Samsara Therapeutics Inc.Samsara Therapeutics is a biotech company developing several novel, orally active autophagy enhancers and demonstrated they can rescue CMT1A neuropathy in mice in a dose-dependent manner.The partnership with Samsara Therapeutics is CMTRF’s largest investment to date and is dedicated toward a project to further optimize pipeline autophagy compounds that may eventually become a treatment option for CMT patients.  About Charcot-Marie-ToothCharcot-Marie-Tooth is a group of inherited, chronic peripheral neuropathies that result in nerve degradation. CMT patients suffer from progressive muscle atrophy of legs and arms causing walking, running and balance problems and abnormal hand and foot functioning. CMT affects one in 2,500 people (about the same prevalence as multiple sclerosis). At the moment, there is no treatment or cure for CMT.BioWin helping ease job issuesBioWin, the health cluster of Wallonia in Belgium, has a Talent Now program which aims to tackle the recruitment challenges in the biotech and medtech industry in Belgium. With the support of Walloon government and private companies (GSK, Janssen, Takeda, etc.), Talent Now is based on a study performed by BioWin that showed potential of close to 1,000 recruitments per year in biomanufacturing and R&D activities in Wallonia.The Talent Now public-private consortium will pave the way for a EU Biotech Campus, set to open in Gosselies in 2025.  e-therapeutics completes £13.5M fundraisee-therapeutics plc, a company integrating computational power and biological data to discover life-transforming RNAi medicines, recently announced a fundraise of £13.5 million before expenses by way of a subscription for new ordinary shares.The fundraise allows the company to generate value and accelerate the next stage of its growth, advancing its position in creating an entirely new template for drug discovery using computation to capture and model disease complexity, identify novel targets and design RNAi drugs against those targets that can be rapidly progressed to the clinic. The net proceeds of the Subscription will be used to facilitate initiatives to accelerate growth, with a focus on expanding the Company’s in-house pipeline of first-in-class RNAi candidates derived from ETX’s computational platform; further developing cell type-specific computational tools and datasets; and general working capital including additional headcount.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter

2:22 Labiotech.eu news4:53 TAU Systems21:54 Bone Health Technologies 33:26 Immutep44:36 JLLThis week, we have conversations with Marc Voigt, CEO of Immutep; Manuel Hegelich, CEO of TAU Systems; and ​​Laura Yecies, CEO of Bone Health Technologies. We also have our weekly chat with global commercial real estate services company JLL, with Travis McCready. FDA fast tracks Immutep non-small cell lung cancer candidateImmutep Limited says the United States Food and Drug Administration (FDA) has granted fast track designation to eftilagimod alpha (efti or IMP321) in combination with pembrolizumab for the treatment of first line non-small cell lung cancer (NSCLC).Efti is the company’s first-in-class soluble LAG-3 clinical stage candidate, which activates antigen presenting cells (APC) to engage both the innate and adaptive immune system to target solid tumors.The designation has been granted for the development of efti in combination with pembrolizumab in first line treatment of stage IIIB/IV NSCLC patients expressing PD-L1 tumor proportion score greater than or equal to 1%, not amenable to EGFR/ALK based therapy. The designation is based on the TACTI-002/KEYNOTE-798 phase II clinical data in first line NSCLC for PD-L1 all-comers.This represents the second fast track designation for efti, following the same designation in April 2021 for efti in combination with pembrolizumab in first line treatment of recurrent or metastatic head and neck squamous cell carcinoma. TAU Systems to build new generation of compact particle accelerators after $15M investmentTAU Systems has raised $15 million in seed investment to bring particle accelerators to a multitude of users by harnessing the latest laser technology to make electrons surf on three-dimensional plasma waves and accelerate them to ultra-high energies.The news is significant as, until now, high-energy particle accelerators have been limited to countries and governmental organizations. Due to their huge size and high cost, access for engineers and biotech professionals is severely limited. The laser-driven particle accelerators and X-ray free-electron lasers (XFEL) developed by TAU Systems will give access to a world of ultra-small objects evolving ultra-fast under ultra-powerful conditions – TAU's team calls it the Ultraverse.TAU Systems said it will offer beamtime, data acquisition and analysis as a full-service supplier as well as complete laser-driven accelerators and XFEL systems for sale, to, for example, pharma and biotech, battery and solar technology, and other material-science driven markets. Bone Health Technologies at ASBMR 2022The American Society for Bone and Mineral Research (ASBMR) annual meeting was held recently in Texas.The ASBMR is a professional, scientific and medical society established to bring together clinical and experimental scientists who are involved in the study of bone and mineral metabolism.One of the companies attending was Bone Health Technologies, a San Francisco-based company that applies science and medical expertise to create better health outcomes for women and men at risk of developing osteoporosis and the associated bone fractures.  The company has created OsteoBoost, the first vibration belt specifically designed to treat osteopenia and prevent osteoporosis.Initially created in the med-tech incubator TheraNova, Bone Health Technologies is poised to become the new standard of care in treating both osteoporosis and osteopenia (the precursor to osteoporosis). SponsorInter

2:08 Labiotech.eu news4:42 Faron Pharmaceuticals15:22 BiotechX20:13 Cultivated Biosciences26:26 EPFLThis week, we have four interviews. Our guests are: Juho Jalkanen, COO of Faron Pharmaceuticals; Ardemis Boghossian and Melania Reggente from the EPFL School of Basic Sciences in Switzerland; Tomas Turner, CEO and co-founder of Cultivated Biosciences; and Joanna Magaji, conference manager for the BiotechX event. BiotechX event taking place in Basel in NovemberBiotechX, an event staged by Terrapinn, is set to open its doors next month.From November 8 to 10, more than 2,000 attendees will head to the Basel Congress Center in Basel, Switzerland, to network, see more than 150 exhibitors, and have a choice of presentations from upwards of 400 speakers. BioTechX is Europe’s largest event covering diagnostics, precision medicine and digital transformation in pharmaceutical development and healthcare.Could combining biotech and photosynthetic bacteria help the energy crisis? A group of researchers in Switzerland is using photosynthetic bacteria to generate energy.After implanting nanotubes into them, the bacteria can create energy. And when the cells divide, those nanotubes stay with subsequent generations. While there’s a long way to go, and many questions to be answered, Ardemis Boghossian at EPFL’s School of Basic Sciences in Switzerland is looking to a potential future where bacteria generate electricity. Faron Pharmaceuticals’ Traumakine data shows promise for militaryFaron Pharmaceuticals Ltd says data from its preclinical salvage, preservation, and advanced resuscitation through endothelial stabilization (SPARES) study was presented at the Military Health System Research Symposium (MHSRS) in Orlando, Florida. The SPARES study was a preclinical study, conducted on non-human primates (a representative model for humans), to understand the potential effects of Traumakine, Faron’s investigational intravenous interferon beta-1a therapy, on limb salvage and preventing multiple organ dysfunction in prolonged field care scenarios where blood flow to a significantly wounded limb is closed for rescue and transportation. Biosciences raises $1.5M to take fats to next frontierCultivated Biosciences, an ingredient startup biotech company founded by Swiss entrepreneurs Tomas Turner and Dimitri Zogg, has just raised a $1.5M pre-seed round. The funding will enable the growing team to further optimize its production processes, research food applications and start product development of its creamy ingredient for dairy alternatives from non-GMO yeast with their first clients.SponsorInterested in sponsoring one or more episodes of the podcast? Learn more here!Leave a review on Apple podcastsReviews are hugely important because they help new people discover this podcast. If you enjoyed listening to this episode, we would love to hear your feedback!Connect with uslabiotech.euSubscribe to our newsletter